COMBI-r – A non-interventional, multi-centric, prospective trial of combined Dabrafenib and Trametinib treatment of advanced melanoma in the real-world setting - Combi-r

Trial Profile

COMBI-r – A non-interventional, multi-centric, prospective trial of combined Dabrafenib and Trametinib treatment of advanced melanoma in the real-world setting - Combi-r

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Dabrafenib (Primary) ; Trametinib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Combi-r
  • Sponsors Novartis Pharma
  • Most Recent Events

    • 07 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top